Word that the U.S. has bought up the entire supply of the COVID-19 drug remdesivir is another reminder that in a pandemic, treatments and vaccines need to be accessible to everyone, globally.
Academic rigor, journalistic flair
Articles on Remdesivir
Displaying 21 - 31 of 31 articles
As the United States risks prompting a bidding war for coronavirus drugs, can the world show solidarity over equitable access to medicines? And is remdesivir any use against COVID-19 anyway?
Treatment nationalism is a threat to us all.
During the last six months, news reports have mentioned dozens of drugs that may be effective against the new coronavirus. Here we lay out the evidence and reveal which ones are proven to work. Or not.
A mutating coronavirus has implications for vaccines, treatments, tests and your future plans.
A simple head-to-head trial would resolve this conflict once and for all.
Gilead’s drug Remdesivir showed preliminary positive results in clinical trials. But what is this drug and how, exactly, does it work?
Preliminary results from a US trial show remdesivir may help in treating COVID-19. But the findings haven’t been peer-reviewed, and the results from other clinical trials have shown little effect.
Vaccines for other diseases are being examined for their protective effects against coronavirus.
Coronavirus drug trials are underway – a virologist explains what the treatment options may be.
Among the more than 20,000 drugs approved by the FDA, there may be some that can treat COVID-19. A team at the University of California, San Francisco, is identifying possible candidates.
Top contributors
-
Assistant Professor of Infectious Diseases, University of Virginia
-
Associate Professor of the School of Pharmacy, University of Sydney
-
Professor of Medicine, University of Virginia
-
Professor of Philosophy, Binghamton University, State University of New York
-
Professor and Director of the Stoneygate Centre for Excellence in Empathic Healthcare, University of Leicester
-
Lecturer Pharmacy Practice, University of Sydney
-
Science communications researcher, Cochrane Australia | Advisor to the Editor in Chief, Cochrane Collaboration, Monash University
-
Joel Lexchin is a Friend of The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
-
Associate professor, School of Pharmacy and Charles Perkins Centre, University of Sydney
-
Lecturer of Law, Global Health, Keele University
-
Senior Lecturer in Pharmacology, Keele University
-
Associate Director of Microbiology, University of California, San Diego
-
Clinical Research Fellow in Viral Immunology and Veterinary Surgeon, University of Cambridge
-
Professor of Cancer Virology, University of Leeds
-
Executive Director, National COVID-19 Clinical Evidence Taskforce, and Professor, School of Public Health and Preventive Medicine, Monash University
